University of Bristol
TrialNet screening is unavailable to residents of the United Kingdom. Please contact email@example.com for more information.
The University of Bristol is one of twenty-two type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Yuk Fun-Liu, MD, the TrialNet team at University of Bristol is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.
Beth ThorneClinical Trials Programme Manager
Samantha LoudPaediatric Research Nurse
Tracey HughesResearch Assistant Practitioner
Depending on your risk screening results, you may be eligible for monitoring. We’ll monitor you for disease progression and let you know if you become eligible for a study. More
TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 or stage 2), and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression. Details
We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D. Details
If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More